Learning From the Past & Spearheading Macrophage Clinical Acceleration

The 6th Macrophage-Directed Therapies Summit is uniting 60+ biopharma and academia leaders across R&D, Discovery, Biology, Translational, and Clinical Development fields for invaluable networking and insights into all facets of macrophage-directed therapies.

Grab your Full Agenda – https://ter.li/nqf2qd

Despite toxicity concerns for CD47 targets in 2023, the macrophage community persists in exploring innovative targets. Their determination to unveil new data showcasing safety and proof of concept remains stronger than ever, revitalizing momentum in this highly promising industry.

This October, you could meet leading experts from Verseau Therapeutics, Inceptor Bio, Carisma Therapeutics, Elpiscience Biopharmaceuticals, John Hopkins School of Medicine, Resolution Therapeutics, and more, offering exclusive insights into their winning strategies for staying ahead of the curve in the years ahead.

Key Highlights:

• Tackling challenges in delivery, administration, animal model selection, reprogramming, manufacturing, and more to optimize choices
• Exploring indications for extending beyond oncology to autoimmunity, inflammation, neurodegenerative diseases, and beyond
• Assessing the evolving macrophage-therapeutics landscape to uncover innovative targets and the latest data

Register Here for the Best Savings – https://ter.li/o22pxt